{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:43:07Z","timestamp":1794526987231,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-019-1338-y","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T09:04:41Z","timestamp":1560330281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study"],"prefix":"10.1186","volume":"19","author":[{"given":"Akram","family":"Sanagoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jouybari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Koohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sayehmiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"issue":"2","key":"1338_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-017-2720-5","volume":"137","author":"EL Zale","year":"2018","unstructured":"Zale EL, Pierre-Louis C, Macklin EA, Riklin E, Vranceanu AM. The impact of a mind\u2013body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis. J Neuro-Oncol. 2018;137(2):321\u20139.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"1338_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/PHM.0000000000000842","volume":"97","author":"A Ngo-Huang","year":"2018","unstructured":"Ngo-Huang A, Yadav R, Fu JB, Liu D, Williams JL, Bruera E, Guo Y. Mobility functional outcomes of neurofibromatosis patients: a preliminary report. Am J Phys Med Rehabil. 2018;97(1):41\u20139.","journal-title":"Am J Phys Med Rehabil"},{"key":"1338_CR3","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"1338_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/qjmed\/hcx071","volume":"110","author":"AK Pannu","year":"2017","unstructured":"Pannu AK, Sharma N. Neurofibromatosis type 1 and disseminated malignant peripheral nerve sheath tumor. QJM. 2017;110(9):583\u20134.","journal-title":"QJM"},{"key":"1338_CR5","first-page":"47","volume":"6","author":"C Lu-Emerson","year":"2009","unstructured":"Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis. 2009;6:47\u201353.","journal-title":"Rev Neurol Dis"},{"issue":"3","key":"1338_CR6","doi-asserted-by":"publisher","first-page":"e26838","DOI":"10.1002\/pbc.26838","volume":"65","author":"S Khatua","year":"2018","unstructured":"Khatua S, Gutmann DH, Packer RJ. Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. Pediatr Blood Cancer. 2018;65(3):e26838. \n                    https:\/\/doi.org\/10.1002\/pbc.26838\n                    \n                   Epub 2017 Oct 19.","journal-title":"Pediatr Blood Cancer"},{"key":"1338_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/jnnp.2010.206532","volume":"10","author":"RE Ferner","year":"2010","unstructured":"Ferner RE. The neurofibromatosis. Pract Neurol. 2010;10:82\u201393.","journal-title":"Pract Neurol"},{"key":"1338_CR8","first-page":"81","volume":"6","author":"C Lu-Emerson","year":"2009","unstructured":"Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis. 2009;6:81\u20136.","journal-title":"Rev Neurol Dis"},{"issue":"1","key":"1338_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-0038-1627471","volume":"38","author":"SR Plotkin","year":"2018","unstructured":"Plotkin SR, Wick A. Neurofibromatosis and schwannomatosis. Semin Neurol. 2018;38(1):73\u201385.","journal-title":"Semin Neurol"},{"key":"1338_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/B978-0-444-52902-2.00054-0","volume":"115","author":"SK Lloyd","year":"2013","unstructured":"Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management. Handb Clin Neurol. 2013;115:957\u201367.","journal-title":"Handb Clin Neurol"},{"key":"1338_CR11","unstructured":"Fayers PM, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes, 2nd Edition. \n                    https:\/\/www.wiley.com\/enus\/Quality+of+Life%3A+The+Assessment%2C+Analysis+and+Interpretation+of+Patient+reported+Outcomes%2C+2nd+Edition-p-9781118699454\n                    \n                  ."},{"key":"1338_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/120347549900300608","volume":"3","author":"MM Chren","year":"1993","unstructured":"Chren MM. Understanding research about quality of life and other health outcomes. J Cutan Med Surg. 1993;3:312\u20136.","journal-title":"J Cutan Med Surg"},{"key":"1338_CR13","volume-title":"Questionario sullo stato di salute SF-36: manual d\u2019uso e guida all\u2019interpretazione dei risultati","author":"G Apolone","year":"1998","unstructured":"Apolone G, Mosconi P, Ware John JR. Questionario sullo stato di salute SF-36: manual d\u2019uso e guida all\u2019interpretazione dei risultati. Milano: Guerini e Associati; 1998."},{"key":"1338_CR14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0895-4356(98)00093-6","volume":"51","author":"A Leplege","year":"1998","unstructured":"Leplege A, Ecosse E, Verdier A, Perneger TV. The French SF-36 health survey. J Clin Epidemiol. 1998;51:1013\u201323.","journal-title":"J Clin Epidemiol"},{"key":"1338_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren MM, Lasel RJ, Quinn LM. Skindex, a quality- of-life measure for patients with skin disease. J Invest Dermatol. 1996;107:707\u201313.","journal-title":"J Invest Dermatol"},{"key":"1338_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1212\/WNL.0000000000003005","volume":"87","author":"A-M Vranceanu","year":"2016","unstructured":"Vranceanu A-M, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR. Mind-body therapy via videoconferencing in patients with neurofibromatosis: an RCT. Neurology. 2016;87:806\u201314.","journal-title":"Neurology"},{"key":"1338_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.psym.2012.09.001","volume":"54","author":"ER Park","year":"2013","unstructured":"Park ER, Traeger L, Vranceanu A-M. The development of a patient-centered program based on the relaxation response: the relaxation response resiliency program (3RP). Psychosomatics. 2013;54:165\u201374.","journal-title":"Psychosomatics"},{"key":"1338_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2345\/0899-8205-49.5.306","volume":"49","author":"M Vockley","year":"2015","unstructured":"Vockley M. The rise of telehealth: \u201ctriple aim,\u201d innovative technology, and popular demand are spearheading new models of health and wellness care. Biomed Instrum Technol Assoc Adv Med Instrum. 2015;49:306\u201320.","journal-title":"Biomed Instrum Technol Assoc Adv Med Instrum"},{"key":"1338_CR19","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/ajmg.a.31422","volume":"140","author":"PZ Page","year":"2006","unstructured":"Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006;140:1893\u20138.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"1338_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000187594","volume":"218","author":"Y Kodra","year":"2009","unstructured":"Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, Taruscio D. Health-related quality of life in patients with neurofibromatosis type 1. Dermatology. 2009;218(3):215\u201320.","journal-title":"Dermatology"},{"key":"1338_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/MAO.0000000000001019","volume":"37","author":"VL Merker","year":"2016","unstructured":"Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W, Plotkin SR. Health-related quality of life of individuals with Neurofibromatosis type 2: results from the NF2 natural history study. Otol Neurotol. 2016;37:574\u20139.","journal-title":"Otol Neurotol"},{"issue":"3","key":"1338_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jpeds.2009.02.056","volume":"155","author":"A Vardarinos","year":"2009","unstructured":"Vardarinos A, Zafeiriou DI, Vargiami E, Pratsidou-Gertsi P, Kontopoulos E, Kanakoudi-Tsakalidou F. Parental reports of health-related quality of life in greek children with neurofibromatosis type 1. J Pediatr. 2009;155(3):453\u20134.","journal-title":"J Pediatr"},{"key":"1338_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jpeds.2007.03.005","volume":"151","author":"R Oostenbrink","year":"2007","unstructured":"Oostenbrink R, Spong K, de Goede-Bolder A, Landgraf JM, Raat H, Moll HA. Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determinants. J Pediatr. 2007;151:182\u20136.","journal-title":"J Pediatr"},{"key":"1338_CR24","first-page":"1421","volume":"137","author":"P Wolkenstein","year":"2001","unstructured":"Wolkenstein P, Zeller J, Revuz J, Ecoss E, Leplege A. Quality of life impairment in neurofibromatosis type 1. Arch Drematol. 2001;137:1421\u20135.","journal-title":"Arch Drematol"},{"key":"1338_CR25","unstructured":"Hornigold, RE; (2015) Impact of Neurofibromatosis 2 on Quality of Life. Doctoral thesis , UCL (University College London). \n                    http:\/\/discovery.ucl.ac.uk\/1473025\/\n                    \n                  . [Green open access]."},{"issue":"3","key":"1338_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jpeds.2008.08.045","volume":"154","author":"LC Krab","year":"2009","unstructured":"Krab LC, Oostenbrink R, de Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior. J Pediatr. 2009;154(3):420\u20135.","journal-title":"J Pediatr"},{"key":"1338_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-0032-1301396","volume":"73","author":"RE Hornigold","year":"2012","unstructured":"Hornigold RE, Golding JF, Leschziner G, Obholzer R, Gleeson MJ, Thomas N. The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2. J Neurol Surg B. 2012;73:104\u201311.","journal-title":"J Neurol Surg B"},{"key":"1338_CR28","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/ajmg.a.36466","volume":"164A","author":"VL Merker","year":"2014","unstructured":"Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with Neurofibromatosis. Am J Med Genet Part A. 2014;164A:1431\u20137.","journal-title":"Am J Med Genet Part A"},{"issue":"5","key":"1338_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/fampra\/19.5.469","volume":"19","author":"M Steiner","year":"2002","unstructured":"Steiner M. Postnatal depression: a few simple questions. Fam Pract. 2002;19(5):469\u201370.","journal-title":"Fam Pract"},{"key":"1338_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","volume":"114","author":"A Vranceanu","year":"2013","unstructured":"Vranceanu A, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neuro-Oncol. 2013;114:257\u201362.","journal-title":"J Neuro-Oncol"},{"key":"1338_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11060-015-1725-1","volume":"122","author":"A Vranceanu","year":"2015","unstructured":"Vranceanu A, Merker VL, Park E, Plotkin SR. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neuro-Oncol. 2015;122:219\u201328.","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"1338_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):65\u201394.","journal-title":"Ann Intern Med"},{"key":"1338_CR33","unstructured":"Wells G, Shea B, O\u2019connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"1338_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jpeds.2006.04.025","volume":"149","author":"A Graf","year":"2006","unstructured":"Graf A, Landolt MA, Capone Mori A, Boltshauser E. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. J Pediatr. 2006;149:348\u201353.","journal-title":"J Pediatr"},{"key":"1338_CR35","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1365-2133.2008.08949.x","volume":"160","author":"P Wolkenstein","year":"2008","unstructured":"Wolkenstein P, Rodriguez D, Ferkal S, Gravier H, Buret V, Algans N, Simeoni MC, Bastuji-Garin S. Impact of neurofibromatosis 1 upon quality of life in childhood: a crosssectional study of 79 cases. Br J Dematol. 2008;160:844\u20138.","journal-title":"Br J Dematol"},{"key":"1338_CR36","doi-asserted-by":"publisher","first-page":"e12174","DOI":"10.1111\/jspn.12174","volume":"22","author":"CB Draucker","year":"2017","unstructured":"Draucker CB, Nutakki K, Varni JW, Swigonski NL. The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: analysis of narratives. J Spec Pediatr Nurs. 2017;22:e12174. \n                    https:\/\/doi.org\/10.1111\/jspn.12174\n                    \n                  .","journal-title":"J Spec Pediatr Nurs"},{"issue":"7","key":"1338_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1469-8749.2010.03624.x","volume":"52","author":"Y Gilboa","year":"2010","unstructured":"Gilboa Y, Rosenblum S, Fattal-Valevski A, Josman N. Application of the international classification of functioning, disability and health: a review. Dev Med Child Neurol. 2010;52(7):612\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1338_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajmg.a.37987","volume":"173","author":"J-S Lai","year":"2017","unstructured":"Lai J-S, Jensen SE, Patel ZS, Listernick R, Charrow J. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan. Am J Med Genet A. 2017;173(1):79\u201387.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"1338_CR39","first-page":"25","volume":"24","author":"S Saltik","year":"2013","unstructured":"Saltik S, Basgul S. Quality of life in children with Neurofibromatosis type 1, based on their mothers reports. Turk Psikiyatri Derg. 2013;24(1):25\u201334.","journal-title":"Turk Psikiyatri Derg"},{"issue":"12","key":"1338_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/gim.2012.85","volume":"14","author":"DL Wang","year":"2012","unstructured":"Wang DL, Smith KB, Esparza S. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012;14(12):977\u201382.","journal-title":"Genet Med"},{"key":"1338_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1740-1445(03)00005-6","volume":"1","author":"N Rumsey","year":"2004","unstructured":"Rumsey N, Harcourt D. Body image and disfigurement: issues and interventions. Body Image. 2004;1:83\u201397.","journal-title":"Body Image"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1338-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T23:06:01Z","timestamp":1591830361000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1338-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1338-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,12]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}